Source Count: 21 | Weighted Score: 54 | Source Confidence: [5/5] | Primary Tier: 2 | Last Updated: March 11, 2026
Keywords: dermatology, skin, melanoma, eczema, psoriasis, dermatopathology, skin cancer, wound healing, cosmetic dermatology, Mohs surgery, biologics, dermatoscopy, skin microbiome, photodermatology
Category Tags: medicine-healing, dermatology, skin-disease, immunology
Cross-References: X_1_01 — History of Medicine · R_1_04 — Biology Overview · X_5_09 — Pharmacology

QUICK SUMMARY

Dermatology is the medical specialty devoted to the diagnosis and management of diseases of the skin, hair, nails, and mucous membranes — the largest and most visible organ system. The skin serves as the body's primary barrier against infection, ultraviolet radiation, dehydration, and mechanical injury, while also functioning as a sensory organ, thermoregulator, and immunological interface. Dermatological conditions range from common disorders affecting billions (acne, eczema/atopic dermatitis, psoriasis, fungal infections) to life-threatening malignancies (melanoma — skin cancer whose incidence has risen dramatically over the past half-century, closely linked to UV exposure). The specialty has undergone major transformations: the development of dermatopathology (microscopic diagnosis of skin diseases — establishing the link between clinical appearance and histological pathology), dermatoscopy (non-invasive magnified visualization of skin lesions for melanoma detection), phototherapy (UV light treatment for psoriasis and vitiligo), Mohs micrographic surgery (the most tissue-sparing technique for skin cancer removal — developed by Frederic Mohs, 1938), and the biologic revolution — targeted immunological therapies (TNF-α inhibitors, IL-17 and IL-23 inhibitors) that have transformed the management of severe psoriasis, atopic dermatitis, and other immune-mediated skin diseases. Emerging frontiers include the skin microbiome, AI-assisted dermatological diagnosis, and gene therapy for inherited skin disorders (epidermolysis bullosa).

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 Skin Structure and Function

• The skin is the largest organ of the human body (~1.7–2.0 m², ~15% of total body weight) — consisting of the epidermis (outermost layer — stratified squamous epithelium with keratinocytes, melanocytes, Langerhans cells, and Merkel cells), dermis (connective tissue with blood vessels, nerves, hair follicles, sweat and sebaceous glands), and subcutis (adipose tissue)
• Barrier function: the stratum corneum (outermost epidermal layer) provides the primary physical and chemical barrier; disrupted barrier function is central to atopic dermatitis/eczema
• Melanin: produced by melanocytes — provides protection against UV radiation damage; variations in melanin production underlie differences in skin color; UV damage to DNA is the primary driver of skin cancer

1.2 Common Skin Diseases

• Atopic dermatitis (eczema): chronic, relapsing inflammatory skin disease affecting ~15–20% of children and ~7–10% of adults in developed countries; characterized by pruritus, erythema, and barrier dysfunction; associated with filaggrin gene mutations, immune dysregulation (Th2-dominant inflammation), and the atopic march (eczema → asthma → allergic rhinitis)
• Psoriasis: chronic immune-mediated inflammatory disease affecting ~2–3% of the global population; characterized by well-demarcated, erythematous plaques with silvery scale; driven by Th17/IL-23 immune pathway; associated with psoriatic arthritis, cardiovascular disease, and metabolic syndrome
• Acne vulgaris: the most common skin disease — affects ~85% of teenagers to some degree; multifactorial pathogenesis: sebum overproduction, follicular hyperkeratinization, Cutibacterium acnes colonization, and inflammation

1.3 Skin Cancer

• Melanoma: the most lethal skin cancer — arising from melanocytes; incidence has increased ~3% per year in many populations over recent decades; strongly associated with UV exposure (particularly intermittent/intense exposure and sunburns), fair skin, and high mole counts; early detection (Breslow thickness <1 mm) is associated with >95% survival; advanced melanoma treatment was revolutionized by immune checkpoint inhibitors (ipilimumab — anti-CTLA-4; nivolumab, pembrolizumab — anti-PD-1)
• Non-melanoma skin cancers (basal cell carcinoma — BCC, and squamous cell carcinoma — SCC): the most common cancers globally (combined incidence exceeding all other cancers); predominantly caused by cumulative UV exposure; rarely metastatic (especially BCC) but can cause significant local destruction
• Mohs micrographic surgery: developed by Frederic Mohs (1938 — refined over subsequent decades); the tumor is progressively excised in thin layers, with each layer examined microscopically for tumor cells until clear margins are achieved — resulting in the highest cure rates (>99% for primary BCC) with maximal tissue preservation; the gold standard for skin cancer on cosmetically and functionally critical sites (face, ears, nose)

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 Biologic Therapies

• Biologic agents have transformed the treatment of moderate-to-severe psoriasis and atopic dermatitis:
• TNF-α inhibitors (etanercept, infliximab, adalimumab — first approved for psoriasis in the 2000s)
• IL-17 inhibitors (secukinumab, ixekizumab) and IL-23 inhibitors (guselkumab, risankizumab) — achieving PASI 90/100 (near-complete skin clearance) in the majority of psoriasis patients
• Dupilumab (anti-IL-4Rα — blocking IL-4 and IL-13): the first biologic approved for moderate-to-severe atopic dermatitis (2017); dramatically improved disease control
• These therapies represent a paradigm shift from broad immunosuppression to targeted immunomodulation

2.2 Dermatoscopy and AI Diagnosis

• Dermatoscopy (dermoscopy): a non-invasive technique using polarized light or oil immersion magnification to visualize subsurface skin structures — improves diagnostic accuracy for melanoma by 5–30% compared to naked-eye examination
• AI-assisted dermatological diagnosis: deep learning algorithms (convolutional neural networks) have demonstrated diagnostic accuracy comparable to board-certified dermatologists for melanoma classification (Esteva et al. 2017, Nature); clinical implementation is progressing but raises concerns about generalizability across skin types, clinical validation, and medicolegal liability

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Skin Microbiome Therapeutics

• The skin microbiome — the community of microorganisms inhabiting the skin surface — is increasingly recognized as playing a role in skin health and disease (atopic dermatitis, acne, wound healing); therapeutic manipulation of the skin microbiome (topical probiotics, bacteriotherapy, microbiome transplantation) is an active research area but has not yet yielded clinically validated products beyond experimental use

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 Tanning Beds as Safe

• [REFUTED] Claims that indoor tanning is safe or provides health benefits — the International Agency for Research on Cancer (IARC) classifies UV-emitting tanning devices as Group 1 carcinogens (2009); indoor tanning significantly increases the risk of melanoma and non-melanoma skin cancers, particularly with first exposure before age 35

Counter-Arguments & Criticisms

No significant counter-arguments exist in the scholarly literature for the core claims in this document. Dermatology: The Science and Medicine of Skin represents established medical science consensus with no active scholarly dispute over the fundamental claims presented here.

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Bolognia, Jean L., Julie V | 2018 | ∅ | Dermatology | ∅ | ∅ | Schaffer, and Lorenzo Cerroni | 4th | ∅ | ∅ | ∅ | Philadelphia: Elsevier
2. Esteva, Andre, et al | 2017 | "Dermatologist-Level Classification of Skin Cancer with Deep Neural Networks" | Nature | ∅ | 542::115–118 | ∅ | ∅ | doi:10.1038/nature21056 | ∅ | ∅ | ∅
3. Mohs, Frederic E | 1941 | "Chemosurgery: A Microscopically Controlled Method of Cancer Excision" | Archives of Surgery | ∅ | 42.2::279–295 | ∅ | ∅ | doi:10.1001/archsurg.1941.01210080079004 | ∅ | ∅ | ∅
4. Nestle, Frank O., Daniel H | 2009 | "Psoriasis" | New England Journal of Medicine | ∅ | 361.5::496–509 | Kaplan, and Jonathan Barker | ∅ | doi:10.1056/nejmra0804595 | ∅ | ∅ | ∅
5. Weidinger, Stephan; Natalija Novak | 2016 | "Atopic Dermatitis" | The Lancet | ∅ | ∅ | 387.10023 : 1109 1122 | ∅ | doi:10.1016/s0140-6736(15)00149-x | ∅ | ∅ | ∅
6. Byrd, Allyson L., Yasmine Belkaid; Julia A | 2018 | "The Human Skin Microbiome" | Nature Reviews Microbiology | ∅ | 16.3::143–155 | Segre | ∅ | doi:10.1038/nrmicro.2017.157 | ∅ | ∅ | ∅
7. International Agency for Research on Cancer (corp.) | 2012 | ∅ | A Review of Human Carcinogens: Radiation | ∅ | ∅ | IARC Monographs Vol | ∅ | ∅ | ∅ | ∅ | 100D; Lyon: IARC
8. Schadendorf, Dirk, et al | 2018 | "Melanoma" | The Lancet | ∅ | ∅ | 392.10151 : 971 984 | ∅ | ∅ | ∅ | ∅ | ∅
9. Elias, Peter M | 2005 | "Stratum Corneum Defensive Functions: An Integrated View" | Journal of Investigative Dermatology | ∅ | 125.2::183–200 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
10. Kabashima, Kenji, et al | 2019 | "The Immunological Anatomy of the Skin" | Nature Reviews Immunology | ∅ | 19::19–30 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
11. Langan, Sinéad M., et al | 2020 | "Atopic Dermatitis" | The Lancet | ∅ | ∅ | 396.10247 : 345 360 | ∅ | ∅ | ∅ | ∅ | ∅
12. Griffiths, Christopher E.M., et al | 2021 | "Psoriasis" | The Lancet | ∅ | ∅ | 397.10281 : 1301 1315 | ∅ | ∅ | ∅ | ∅ | ∅
13. Armstrong, April W.; Charlotte Read | 2020 | "Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review" | JAMA | ∅ | 323.19::1945–1960 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
14. Tsoi, Lam C., et al | 2012 | "Identification of 15 New Psoriasis Susceptibility Loci Highlights the Role of Innate Immunity" | Nature Genetics | ∅ | 44.12::1341–1348 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
15. Grice, Elizabeth A.; Julia A | 2011 | "The Skin Microbiome" | Nature Reviews Microbiology | ∅ | 9.4::244–253 | Segre | ∅ | ∅ | ∅ | ∅ | ∅
16. McKee, Phillip H., Eduardo Calonje; Scott R | 2012 | ∅ | Pathology of the Skin | ∅ | ∅ | Granter. | 4th | ∅ | ∅ | ∅ | Edinburgh: Elsevier
17. Haenssle, Holger A., et al | 2018 | "Man Against Machine: Diagnostic Performance of a Deep Learning Convolutional Neural Network for Dermoscopic Melanoma Recognition in Comparison to 58 Dermatologists" | Annals of Oncology | ∅ | 29.8::1836–1842 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
18. Robert, Caroline, et al | 2015 | "Pembrolizumab Versus Ipilimumab in Advanced Melanoma" | New England Journal of Medicine | ∅ | 372.26::2521–2532 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
19. Kirtschig, Gudula | 2016 | "Lichen Sclerosus — Presentation, Diagnosis and Management" | Deutsches Ärzteblatt International | ∅ | 113.19::337–343 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
20. Bikle, Daniel D | 2014 | "Vitamin D Metabolism, Mechanism of Action, and Clinical Applications" | Chemistry & Biology | ∅ | 21.3::319–329 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
21. Rittié, Laure; Gary J | 2015 | "Natural and Sun-Induced Aging of Human Skin" | Cold Spring Harbor Perspectives in Medicine | ∅ | 5.1:: | Fisher. a015370 | ∅ | ∅ | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: March 11, 2026

Corrections

• 1 truncated DOI in the bibliography reassembled — Elsevier identifiers of the form 10.1016/0004-6981(72)90076-5 contain a parenthesised year, and an upstream parse treated the opening bracket as a field break: each DOI was cut short and its tail ()90076-5) left stranded in a neighbouring column. The two halves were rejoined from this same line — it was then confirmed to resolve against Crossref before being written, so no identifier was reconstructed on faith. Repaired: 10.1016/s0140-6736(15)00149-x. Corpus hygiene campaign, Phase 4, 2026-07-29.